Comparative Investment Analysis of Amgen and Iovance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Source: NASDAQ.COM
- Amgen's Financial Stability: Amgen reported nearly $36.7 billion in revenue for FY 2025, reflecting a 9.9% increase year-over-year, which supported a net income of approximately $7.7 billion, showcasing its strong market position and profitability across over 50 countries.
- Iovance's Growth Potential: Iovance achieved approximately $263.5 million in revenue for FY 2025, a 60.6% increase, despite a net loss of nearly $391 million, indicating that its innovative tumor-infiltrating lymphocyte therapies could offer significant market expansion opportunities in the future.
- Risks and Challenges: Amgen faces risks from government pricing regulations and competition from biosimilars, while Iovance must navigate the complexities of manufacturing personalized therapies and uncertainties regarding market adoption, which could impact their future profitability.
- Investor Considerations: Investors must weigh the stability of Amgen against the high-reward potential of Iovance, with Amgen appealing to conservative investors due to its steady earnings and dividends, while Iovance may attract those seeking high-risk, high-reward opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise
24 Analyst Rating
14 Buy
9 Hold
1 Sell
Moderate Buy
Current: 344.720
Low
280.00
Averages
363.10
High
425.00
Current: 344.720
Low
280.00
Averages
363.10
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Comparison: Amgen vs. Iovance Biotherapeutics
- Amgen's Stability: In FY 2025, Amgen reported nearly $36.7 billion in revenue, reflecting a 9.9% year-over-year growth, with a net income of approximately $7.7 billion and a net margin of about 21%, showcasing its strong profitability and stability in the global market.
- Iovance's Growth Potential: Iovance reported revenue of approximately $263.5 million in FY 2025, marking a 60.6% increase, although it faced a net loss of nearly $391 million with a negative net margin of 148.4%, indicating significant investment in its innovative tumor-infiltrating lymphocyte therapies.
- Risks and Challenges: Amgen is exposed to risks from government pricing regulations and competition from biosimilars, while Iovance must navigate the complexities of manufacturing personalized therapies and uncertainties regarding market adoption, which could impact their future performance.
- Investment Choice: While Iovance shows rapid growth potential in cancer treatment, Amgen, as a mature biotech firm with stable earnings and consistent dividend payments, may be more suitable for investors seeking lower-risk opportunities.
See More
Comparative Investment Analysis of Amgen and Iovance
- Amgen's Financial Stability: Amgen reported nearly $36.7 billion in revenue for FY 2025, reflecting a 9.9% increase year-over-year, which supported a net income of approximately $7.7 billion, showcasing its strong market position and profitability across over 50 countries.
- Iovance's Growth Potential: Iovance achieved approximately $263.5 million in revenue for FY 2025, a 60.6% increase, despite a net loss of nearly $391 million, indicating that its innovative tumor-infiltrating lymphocyte therapies could offer significant market expansion opportunities in the future.
- Risks and Challenges: Amgen faces risks from government pricing regulations and competition from biosimilars, while Iovance must navigate the complexities of manufacturing personalized therapies and uncertainties regarding market adoption, which could impact their future profitability.
- Investor Considerations: Investors must weigh the stability of Amgen against the high-reward potential of Iovance, with Amgen appealing to conservative investors due to its steady earnings and dividends, while Iovance may attract those seeking high-risk, high-reward opportunities.
See More
Amgen vs Iovance: Investment Comparison
- Amgen's Stability: In FY 2025, Amgen reported nearly $36.7 billion in revenue, a 9.9% increase year-over-year, with a net income of approximately $7.7 billion and a net margin of about 21%, showcasing its strong profitability and stability in the global market.
- Iovance's Rapid Growth: Iovance achieved approximately $263.5 million in revenue for FY 2025, marking a 60.6% increase, yet it reported a net loss of nearly $391 million, indicating its innovative potential in cancer treatment but highlighting its lack of profitability.
- Risk Comparison: Amgen faces risks from government pricing regulations and competition from biosimilars, while Iovance must navigate the complexities of manufacturing personalized therapies and uncertainties regarding market adoption, which could impact their future market performance.
- Valuation Differences: Amgen has a forward P/E ratio of 15.1, reflecting its value as a mature company, whereas Iovance, still unprofitable, has a P/S ratio of 5.4, indicating its high-risk investment profile in the early growth stage.
See More
Regeneron and Amgen's Promising Weight Loss Candidates
- Clinical Trial Progress: Regeneron plans to initiate phase 3 clinical trials for its weight-loss candidate olatorepatide this year, which demonstrated up to 19% weight loss in a 48-week study in China, indicating significant potential in the weight loss market; approval in the U.S. could further boost the company's revenue growth.
- Strong Financial Performance: Regeneron's revenue surged by 19% year-over-year to $3.6 billion in Q1, showcasing resilience despite biosimilar competition for Eylea, with sales of a new high-dose formulation growing rapidly, reflecting the company's adaptability in the biopharmaceutical sector.
- Amgen's Competitive Edge: Amgen is conducting phase 3 studies for its anti-obesity drug MariTide, which targets chronic weight management, type 2 diabetes, and cardiovascular outcomes; approval across multiple indications could pose a substantial challenge to market leaders, driving future revenue growth for the company.
- Dividend Appeal: Amgen has increased its dividends annually since 2011, currently offering a forward yield of 3%, significantly higher than the S&P 500 average, attracting long-term investors while providing additional income security for shareholders interested in weight-loss stocks.
See More
Emerging Stars in Weight Loss: Regeneron and Amgen
- Regeneron Clinical Progress: Regeneron plans to initiate phase 3 trials for its weight-loss candidate olatorepatide this year, which demonstrated up to 19% weight loss in a 48-week study in China, indicating strong potential in the weight-loss market; approval in the U.S. could significantly boost the company's growth.
- Strong Financial Performance: Regeneron's revenue surged 19% year-over-year to $3.6 billion in Q1, and despite facing biosimilar competition for Eylea, the sales growth of a new high-dose formulation reflects a solid financial foundation beyond weight-loss drugs.
- Amgen's Drug Development: Amgen is conducting phase 3 studies for its anti-obesity drug MariTide, which, if approved, will target chronic weight management and type 2 diabetes, potentially positioning it as a formidable competitor to Zepbound and expanding market share.
- Stable Dividend Yield: Amgen's revenue rose 6% year-over-year to $8.6 billion in Q1, and despite losing patent exclusivity for denosumab, strong sales from other products like Tezspire and Tepezza, along with consistent dividend increases since 2011, make it attractive for long-term investors.
See More
Comparing Investment Prospects of Amgen and NovoCure
- Amgen's Financial Performance: In FY 2025, Amgen's revenue reached $36.8 billion, reflecting a 10.1% growth with a net income of $7.7 billion, showcasing its strong market position in chronic disease treatments, although high customer concentration poses risks.
- NovoCure's Unique Model: NovoCure generated approximately $655.4 million in FY 2025, an 8.3% increase, but reported a net loss of nearly $136.2 million, highlighting the high costs associated with expanding its product reach.
- Debt and Cash Flow: Amgen's debt-to-equity ratio stands at 6.3x, indicating heavy reliance on borrowed funds, yet it generated $8.1 billion in free cash flow, demonstrating robust cash generation; in contrast, NovoCure's ratio is 0.9x with negative free cash flow of $75.7 million, indicating significant funding needs.
- Market Competition and Outlook: Amgen faces regulatory pressures, particularly from the Inflation Reduction Act, while NovoCure relies on stringent regulatory approvals and payer coverage, with its core product recently FDA-approved, yet future growth potential appears limited.
See More
Investment Comparison: Amgen vs. Iovance Biotherapeutics
- Amgen's Stability: In FY 2025, Amgen reported nearly $36.7 billion in revenue, reflecting a 9.9% year-over-year growth, with a net income of approximately $7.7 billion and a net margin of about 21%, showcasing its strong profitability and stability in the global market.
- Iovance's Growth Potential: Iovance reported revenue of approximately $263.5 million in FY 2025, marking a 60.6% increase, although it faced a net loss of nearly $391 million with a negative net margin of 148.4%, indicating significant investment in its innovative tumor-infiltrating lymphocyte therapies.
- Risks and Challenges: Amgen is exposed to risks from government pricing regulations and competition from biosimilars, while Iovance must navigate the complexities of manufacturing personalized therapies and uncertainties regarding market adoption, which could impact their future performance.
- Investment Choice: While Iovance shows rapid growth potential in cancer treatment, Amgen, as a mature biotech firm with stable earnings and consistent dividend payments, may be more suitable for investors seeking lower-risk opportunities.
See More
Comparative Investment Analysis of Amgen and Iovance
- Amgen's Financial Stability: Amgen reported nearly $36.7 billion in revenue for FY 2025, reflecting a 9.9% increase year-over-year, which supported a net income of approximately $7.7 billion, showcasing its strong market position and profitability across over 50 countries.
- Iovance's Growth Potential: Iovance achieved approximately $263.5 million in revenue for FY 2025, a 60.6% increase, despite a net loss of nearly $391 million, indicating that its innovative tumor-infiltrating lymphocyte therapies could offer significant market expansion opportunities in the future.
- Risks and Challenges: Amgen faces risks from government pricing regulations and competition from biosimilars, while Iovance must navigate the complexities of manufacturing personalized therapies and uncertainties regarding market adoption, which could impact their future profitability.
- Investor Considerations: Investors must weigh the stability of Amgen against the high-reward potential of Iovance, with Amgen appealing to conservative investors due to its steady earnings and dividends, while Iovance may attract those seeking high-risk, high-reward opportunities.
See More
Amgen vs Iovance: Investment Comparison
- Amgen's Stability: In FY 2025, Amgen reported nearly $36.7 billion in revenue, a 9.9% increase year-over-year, with a net income of approximately $7.7 billion and a net margin of about 21%, showcasing its strong profitability and stability in the global market.
- Iovance's Rapid Growth: Iovance achieved approximately $263.5 million in revenue for FY 2025, marking a 60.6% increase, yet it reported a net loss of nearly $391 million, indicating its innovative potential in cancer treatment but highlighting its lack of profitability.
- Risk Comparison: Amgen faces risks from government pricing regulations and competition from biosimilars, while Iovance must navigate the complexities of manufacturing personalized therapies and uncertainties regarding market adoption, which could impact their future market performance.
- Valuation Differences: Amgen has a forward P/E ratio of 15.1, reflecting its value as a mature company, whereas Iovance, still unprofitable, has a P/S ratio of 5.4, indicating its high-risk investment profile in the early growth stage.
See More
Regeneron and Amgen's Promising Weight Loss Candidates
- Clinical Trial Progress: Regeneron plans to initiate phase 3 clinical trials for its weight-loss candidate olatorepatide this year, which demonstrated up to 19% weight loss in a 48-week study in China, indicating significant potential in the weight loss market; approval in the U.S. could further boost the company's revenue growth.
- Strong Financial Performance: Regeneron's revenue surged by 19% year-over-year to $3.6 billion in Q1, showcasing resilience despite biosimilar competition for Eylea, with sales of a new high-dose formulation growing rapidly, reflecting the company's adaptability in the biopharmaceutical sector.
- Amgen's Competitive Edge: Amgen is conducting phase 3 studies for its anti-obesity drug MariTide, which targets chronic weight management, type 2 diabetes, and cardiovascular outcomes; approval across multiple indications could pose a substantial challenge to market leaders, driving future revenue growth for the company.
- Dividend Appeal: Amgen has increased its dividends annually since 2011, currently offering a forward yield of 3%, significantly higher than the S&P 500 average, attracting long-term investors while providing additional income security for shareholders interested in weight-loss stocks.
See More
Emerging Stars in Weight Loss: Regeneron and Amgen
- Regeneron Clinical Progress: Regeneron plans to initiate phase 3 trials for its weight-loss candidate olatorepatide this year, which demonstrated up to 19% weight loss in a 48-week study in China, indicating strong potential in the weight-loss market; approval in the U.S. could significantly boost the company's growth.
- Strong Financial Performance: Regeneron's revenue surged 19% year-over-year to $3.6 billion in Q1, and despite facing biosimilar competition for Eylea, the sales growth of a new high-dose formulation reflects a solid financial foundation beyond weight-loss drugs.
- Amgen's Drug Development: Amgen is conducting phase 3 studies for its anti-obesity drug MariTide, which, if approved, will target chronic weight management and type 2 diabetes, potentially positioning it as a formidable competitor to Zepbound and expanding market share.
- Stable Dividend Yield: Amgen's revenue rose 6% year-over-year to $8.6 billion in Q1, and despite losing patent exclusivity for denosumab, strong sales from other products like Tezspire and Tepezza, along with consistent dividend increases since 2011, make it attractive for long-term investors.
See More
Comparing Investment Prospects of Amgen and NovoCure
- Amgen's Financial Performance: In FY 2025, Amgen's revenue reached $36.8 billion, reflecting a 10.1% growth with a net income of $7.7 billion, showcasing its strong market position in chronic disease treatments, although high customer concentration poses risks.
- NovoCure's Unique Model: NovoCure generated approximately $655.4 million in FY 2025, an 8.3% increase, but reported a net loss of nearly $136.2 million, highlighting the high costs associated with expanding its product reach.
- Debt and Cash Flow: Amgen's debt-to-equity ratio stands at 6.3x, indicating heavy reliance on borrowed funds, yet it generated $8.1 billion in free cash flow, demonstrating robust cash generation; in contrast, NovoCure's ratio is 0.9x with negative free cash flow of $75.7 million, indicating significant funding needs.
- Market Competition and Outlook: Amgen faces regulatory pressures, particularly from the Inflation Reduction Act, while NovoCure relies on stringent regulatory approvals and payer coverage, with its core product recently FDA-approved, yet future growth potential appears limited.
See More
